Direct hemoperfusion using polymyxin B-immobilized fiber (PMX-DHP) is an established treatment method for septic shock caused by Gram-negative infections. We report one instance in which PMX-DHP therapy has been used successfully in a 33-year-old woman with septic shock from urosepsis. Although there is lack of recommendations in latest Surviving Sepsis Campaign Guidelines, evidence of PMX-DHP efficacy in this subset of patients is growing.

1.
Shigemura
K
,
Tanaka
K
,
Adachi
M
,
Yamashita
M
,
Arakawa
S
,
Fujisawa
M
, et al
Chronological change of antibiotic use and antibiotic resistance in Escherichia coli causing urinary tract infections
.
J Infect Chemother
.
2011 Jan 1
;
17
(
5
):
646
51
.
2.
Jiang
Y
,
Li
J
,
Zhang
Y
,
Hu
X
,
Zhang
X
,
Shang
X
, et al
Clinical situations of bacteriology and prognosis in patients with urosepsis
.
Biomed Res Int
.
2019
;
2019
:
1
9
.
3.
Suzuki
Y
,
Kojika
M
,
Sato
H
,
Inoue
Y
,
Endo
S
.
Clinical effects of polymyxin B hemoperfusion in patients with septic shock caused by urinary tract infection
.
Ther Apher Dial
.
2019
;
23
(
1
):
80
5
.
4.
Weis
S
,
Dickmann
P
,
Pletz
MW
,
Coldewey
SM
,
Gerlach
H
,
Bauer
M
.
The third international consensus definitions for sepsis and septic shock (sepsis-3)
.
Dtsch Arztebl Int
.
2017
;
114
(
29–30
):
801
10
.
5.
Shimizu
T
,
Miyake
T
,
Tani
M
.
History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock
.
Ann Gastroenterol Surg
.
2017
;
1
(
2
):
105
13
.
6.
Zhou
F
,
Peng
Z
,
Murugan
R
,
Kellum
JA
.
Blood purification and mortality in sepsis: a meta-analysis of randomized trials
.
Crit Care Med
.
2013
;
41
(
9
):
2209
20
.
7.
Cruz
DN
,
Antonelli
M
,
Fumagalli
R
,
Foltran
F
,
Brienza
N
,
Donati
A
, et al
Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial
.
JAMA
.
2009
;
301
(
23
):
2445
52
.
8.
Esteban
E
,
Ferrer
R
,
Alsina
L
,
Artigas
A
.
Immunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridge
.
Mediat Inflamm
.
2013
;
2013
:
1
12
.
9.
Nakamura
T
,
Sato
E
,
Fujiwara
N
,
Kawagoe
Y
,
Maeda
S
,
Yamagishi
S
.
Suppression of high-mobility group box-1 and receptor for advanced glycation end-product axis by polymyxin B-immobilized fiber hemoperfusion in septic shock patients
.
J Crit Care
.
2011
;
26
(
6
):
546
9
.
10.
Takahashi
G
,
Hoshikawa
K
,
Matsumoto
N
,
Shozushima
T
,
Onodera
C
,
Kan
S
, et al
Changes in serum S100A12 and sRAGE associated with improvement of the PaO2/FiO2 ratio following PMX-DHP therapy for postoperative septic shock
.
Eur Surg Res
.
2011
;
47
(
3
):
135
40
.
11.
Srisawat
N
,
Tungsanga
S
,
Lumlertgul
N
,
Komaenthammasophon
C
,
Peerapornratana
S
,
Thamrongsat
N
, et al
The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients
.
Crit Care
.
2018
;
22
(
1
):
279
.
12.
Rhodes
A
,
Evans
LE
,
Alhazzani
W
,
Levy
MM
,
Antonelli
M
,
Ferrer
R
, et al
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016
.
Intensive Care Med
.
2017
;
43
(
3
):
304
77
.
13.
Klein
DJ
,
Foster
D
,
Walker
PM
,
Bagshaw
SM
,
Mekonnen
H
,
Antonelli
M
.
Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial
.
Intensive Care Med
.
2018
;
44
(
12
):
2205
12
.
14.
Andreis
DT
,
Singer
M
.
Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum
.
Intensive Care Med
.
2016
;
42
(
9
):
1387
97
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.